RAPICLAV 156.25 SUSPENSION

Indications

• Bacterial infections caused by beta-lactamase producing organisms
• Community-acquired pneumonia
• Respiratory tract infections
• Urinary tract infections
• Skin and soft tissue infections

Dosage

Children: Paediatric dosing of clavulanate should be determined based on the specific indication and the formulation used. Refer to the BNF for

Adults: The usual adult dose of clavulanate varies depending on the specific antibiotic it is combined with, generally ranging from 125 mg to 250 mg, taken every 8 hours when combined with amoxicillin.

Mechanism of action

Clavulanate works by irreversibly binding to the active site of beta-lactamase enzymes. By inhibiting these enzymes, clavulanate protects beta-lactam antibiotics from degradation, allowing them to exert their antibacterial effects effectively. This mechanism enhances the spectrum of activity of the co-administered antibiotic, thereby improving clinical outcomes in infections caused by beta-lactamase producing organisms.

Pharmacodynamics

Clavulanate exhibits a time-dependent antibacterial effect, characterized by its ability to maintain effective concentrations against beta-lactamase producing bacteria. Its pharmacodynamic properties are mainly influenced by its interaction with beta-lactam antibiotics, enhancing their efficacy in treating infections. The overall effect is a synergistic relationship that increases the potency of the antibiotic treatment.

Pharmacokinetics

Clavulanate is usually administered orally or parenterally, and it is rapidly absorbed from the gastrointestinal tract. It reaches peak plasma concentrations within 1 to 2 hours after administration. The drug is widely distributed in body tissues, with a volume of distribution indicative of good tissue penetration. Clavulanate undergoes hepatic metabolism, primarily by conjugation, and is excreted largely in the urine as metabolites. The elimination half-life is approximately 1 hour, necessitating frequent dosing for optimal therapeutic effect.

Contra-indications

• Hypersensitivity to clavulanate or any component of the formulation
• History of jaundice or hepatic impairment related to previous use of beta-lactam antibiotics

Adverse effects

• Diarrhea
• Nausea
• Vomiting
• Rash
• Hepatic dysfunction
• Allergic reactions

Interactions

• Probenecid may increase concentrations of clavulanate
• Anticoagulants may have altered effects due to changes in gut flora

Precautions

• Monitor liver function during prolonged therapy
• Use cautiously in patients with renal impairment
• Assess for history of allergy to penicillins or cephalosporins

Pregnancy

Clavulanate is classified as category B. Animal studies have not shown teratogenic effects, but adequate and well-controlled studies in pregnant women are lacking.

Breast-feeding

Clavulanate is excreted in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Formulations

• Clavulanate potassium 125 mg/5 mL
• Clavulanate potassium 250 mg/5 mL

Indications

• Pediatric dosing adjustments
• Intravenous therapy
• Intramuscular injections
• Topical applications
• Oral medications for easier swallowing

Dosage

Children: Refer to the BNF for Children for appropriate dosing adjustments based on age and weight.

Adults: Refer to specific drug guidelines for appropriate dilution and dosage based on the active ingredient.

Mechanism of action

The mechanism of action of a diluted drug depends on the specific active ingredient within the solution. Generally, when a drug is diluted, its pharmacological effects are proportional to its concentration. The active molecules interact with specific receptors or enzymes in the body, leading to a desired therapeutic effect. For example, an analgesic diluted for oral administration will still bind to pain receptors, albeit at a lower intensity compared to its concentrated form.

Pharmacodynamics

Pharmacodynamics refers to the relationship between drug concentration and its effect on the body. In diluted solutions, the pharmacodynamic properties of the active ingredient remain intact, though the therapeutic effect may be reduced due to the lower concentration. The efficacy of the drug is influenced by factors such as receptor affinity, intrinsic activity, and the presence of other substances in the formulation.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of drugs. For diluted drugs, absorption can be affected by the dilution medium, which may enhance or delay the onset of action. Distribution is generally influenced by the volume of distribution of the active ingredient. Metabolism occurs primarily in the liver, where the drug is biotransformed, and excretion is typically via the kidneys. The pharmacokinetic profile may differ based on the dilution level and formulation.

Pregnancy

Consult a healthcare provider, as the effects of diluted preparations can vary depending on the active ingredient.

Breast-feeding

Consult a healthcare provider, as the safety of diluted preparations during breastfeeding can depend on the active ingredient.

Storage

Store in a cool, dry place away from direct sunlight. Ensure that the specific active ingredient's storage requirements are followed.